- Home
- VYNE vs KPRX Comparison
VYNE vs KPRX Comparison
Compare VYNE & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- KPRX
- Stock Information
- Founded
- VYNE 2003
- KPRX 1998
- Country
- VYNE United States
- KPRX United States
- Employees
- VYNE N/A
- KPRX N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VYNE Health Care
- KPRX Health Care
- Exchange
- VYNE Nasdaq
- KPRX Nasdaq
- Market Cap
- VYNE 7.9M
- KPRX 8.7M
- IPO Year
- VYNE 2018
- KPRX N/A
- Fundamental
- Price
- VYNE $0.30
- KPRX $2.71
- Analyst Decision
- VYNE Buy
- KPRX Strong Buy
- Analyst Count
- VYNE 2
- KPRX 1
- Target Price
- VYNE $8.00
- KPRX $10.00
- AVG Volume (30 Days)
- VYNE 1.9M
- KPRX 80.3K
- Earning Date
- VYNE 11-06-2025
- KPRX 11-07-2025
- Dividend Yield
- VYNE N/A
- KPRX N/A
- EPS Growth
- VYNE N/A
- KPRX N/A
- EPS
- VYNE N/A
- KPRX N/A
- Revenue
- VYNE $476,000.00
- KPRX N/A
- Revenue This Year
- VYNE N/A
- KPRX N/A
- Revenue Next Year
- VYNE N/A
- KPRX N/A
- P/E Ratio
- VYNE N/A
- KPRX N/A
- Revenue Growth
- VYNE N/A
- KPRX N/A
- 52 Week Low
- VYNE $0.29
- KPRX $2.25
- 52 Week High
- VYNE $4.30
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- VYNE 28.46
- KPRX 48.49
- Support Level
- VYNE $0.32
- KPRX $2.67
- Resistance Level
- VYNE $0.33
- KPRX $2.90
- Average True Range (ATR)
- VYNE 0.02
- KPRX 0.14
- MACD
- VYNE 0.03
- KPRX 0.01
- Stochastic Oscillator
- VYNE 11.44
- KPRX 39.13
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.